BioSpace News Archive

The data are being presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually.

- Despite being recognized by leading authorities as a serious disease, obesity remains stigmatized, resulting in patients being underdiagnosed and significantly undertreated - Approval includes results from STEP 1, a clinical trial where once-weekly, prescription GLP-1 receptor agonist Wegovy™ (semaglutide) injection 2.4 mg, demonstrated an average weight loss of ~15% at 68-weeks when used with a reduced calorie meal plan and increased physical activity

Surface Oncology announced a clinical trial collaboration with Roche to evaluate SRF388, Surface’s investigational anti-IL-27 antibody, in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma.

Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today presented the first results from the interventional PATHFINDER study evaluating Galleri™, a multi-cancer early detection

The Association of Community Cancer Centers (ACCC) today announced the launch of the ACCC Community Oncology Research Institute (ACORI), building on its existing mission to close the gap in cancer research through optimal community oncology partnerships.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Wall Street veteran Carol Schafer to its board of directors, effective June 3, 2021.

Daré Bioscience, Inc., a leader in women’s health innovation, announced that it has been selected to deliver a company presentation at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 11 new employees.

Delix Therapeutics (the “Company”), a preclinical neuroscience company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced the inaugural members of its Scientific and Strategic Advisory Board.